Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Xintela: Activities below the surface - VH Corp

Xintela

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
• An interim analysis of the OA study is expected in Q1 2025
• Agreement with Region Östergötland regarding GMP production
• We keep the fair value at SEK 1.30 per share

Xintela recently extended the follow-up of the patients in the highest dose level group by six months in its OA study. The company expects an interim analysis from the 18-month follow-up in Q1 2025. Region Östergötland has assigned Xintela to develop and establish a GMP process for autologous skin cells for the treatment of burns. The deal is worth MSEK 3.6. Awaiting the license deal with EQGen Biomedical to materialise, we keep the fair value at SEK 1.30 per share.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.